Awaiting development: Guidance and quality standards

Showing 21 to 30 of 309

Guidance and quality standards awaiting development
Title	Type
Baloxavir marboxil for Influenza [ID6552]	Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]	Technology appraisal guidance
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]	Technology appraisal guidance
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]	Technology appraisal guidance
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]	Technology appraisal guidance
Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [TSID12229]	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]	Technology appraisal guidance